Sanofi Announces Upcoming Launch of MyStar Connect®

Vienna, Austria (ots) -

- MyStar Connect® software contributes to Sanofi's commitment in
providing integrated diabetes care solutions, and supports
healthcare professionals in clinical decision-making -
- CE mark for MyStar Connect® -

At the 50th annual meeting of the European Association for the
Study of Diabetes (EASD) in Vienna, Austria, Sanofi (EURONEXT: SAN
and NYSE: SNY) announced today the upcoming launch of MyStar
Connect®, an easy-to-use, comprehensive diabetes data management
software platform for healthcare professionals (HCPs).

MyStar Connect® will support HCPs in the delivery of
individualised patient care by providing necessary insights and
analysis to optimise diabetes management. The new software is part of
the MyStar® portfolio consisting of medical devices, support services
and guidance and connects to Sanofi's BGStar® and MyStar Extra® blood
glucose meters.

"At Sanofi, our integrated care strategy, rather than just
developing drugs alone, aims to support people with diabetes
holistically, improving patient experiences and outcomes," said
Pierre Chancel, Senior Vice President, Global Diabetes, Sanofi. "The
upcoming launch of MyStar Connect® is another step forward in
Sanofi's long term commitment to improve diabetes care, helping to
streamline and simplify the way HCPs can access and visualise their
patients' blood glucose data."

MyStar Connect® supports clinical decision-making

Research has shown that too much information can cause confusion
whereas integrating and simplifying data management has the opposite
effect.(1),(2) MyStar Connect® automates data collection from
Sanofi's BGStar® and MyStar Extra® blood glucose meters, and safely
stores all the patients' data in between visits. MyStar Connect's
comprehensive and intuitive dashboard enables HCPs to set personal
targets for each patient and quickly review their key metrics,
targets and trends. By making use of colour coding to indicate
personal target achievements and trend arrows that summarise changes
over time, MyStar Connect® helps HCPs to easily identify trends and
key areas needing attention and thus supports their clinical
decision-making for each individual patient.3

Enhancing patient understanding of health-related data Successful
diabetes management requires a high level of patient involvement in
self-monitoring and care. With MyStar Connect®, HCPs will be able to
help people with diabetes to improve their understanding of the
disease and therapy progress by sharing and discussing with them
easy-to-read reports.(3)

The CE mark for MyStar Connect® was obtained by Meteda, the
developer of the software in partnership with Sanofi.

Now approved in Europe, MyStar Connect® will be available in
selected European countries in the beginning of 2015 and will
complement the MyStar® portfolio of Sanofi, combining devices,
services and guidance for simple and effective diabetes management.

About Diabetes

Diabetes is a chronic disease that occurs as type 1 diabetes,
which is an autoimmune disease characterised by the lack of insulin
(the hormone that regulates blood glucose concentrations) production
by the pancreas, and type 2, a metabolic disorder in which there are
two main biological defects: a deficient production of insulin and
reduced ability of the body to respond to the insulin being produced.
Type 1 and type 2 diabetes are characterised by an increase in blood
glucose concentrations (hyperglycemia). Over time, uncontrolled
hyperglycemia leads to the macrovascular and microvascular
complications of diabetes. Macrovascular complications, which affect
the large blood vessels, include heart attack, stroke and peripheral
vascular disease. Microvascular complications affect the small blood
vessels of the eyes (retinopathy), kidney (nephropathy) and nerves
(neuropathy). The global incidence of diabetes is growing at an
alarming rate, with more than 382 million people worldwide living
with the condition today.(4)

About Sanofi Diabetes Sanofi strives to help people manage the
complex challenge of diabetes by delivering innovative, integrated
and personalized solutions. Driven by valuable insights that come
from listening to and engaging with people living with diabetes, the
Company is forming partnerships to offer diagnostics, therapies,
services, and devices including blood glucose monitoring systems.
Sanofi markets both injectable and oral medications for people with
type 1 or type 2 diabetes.

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs. Sanofi
has core strengths in the field of healthcare with seven growth
platforms: diabetes solutions, human vaccines, innovative drugs,
consumer healthcare, emerging markets, animal health and the new
Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York
(NYSE: SNY).

About Meteda

Meteda develops and markets innovative solutions in the field of
medicine, telemedicine and lifestyle. In particular, its activity
deals with the development of advanced software and hardware to
manage diabetes. Meteda's mission is to develop innovative and unique
solutions to improve people's lifestyle and healthcare; building on
an extensive experience and knowledge in the IT medical sector.

To find out more about the MyStar® portfolio of medical devices,
support services and guidance, please visit our MyStar® newsroom:
www.newsroom.mystarsanofi.com

References

(1.) Rodbard D. Optimizing display, analysis, interpretation and
utility of self-monitoring of blood glucose (SMBG) data for
management of patients with diabetes. J Diabetes Sci Technol.
2007;1:62-71.
(2.) Berner ES, Moss J. Informatics challenges for the impending
patient information explosion. J Am Med Inform Assoc 2005;
12:614-7.
(3.) Data on file: MyStar Connect Assessment - Internal study.
(4.) International Diabetes Federation Facts and Figures
http://www.idf.org/worlddiabetesday/toolkit/gp/facts-figures
(Accessed: August 14, 2014).

Forward Looking Statements

Sanofi Forward Looking Statements

This press release contains forward-looking statements as defined
in the Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical
facts. These statements include projections and estimates and their
underlying assumptions, statements regarding plans, objectives,
intentions and expectations with respect to future financial results,
events, operations, services, product development and potential, and
statements regarding future performance. Forward- looking statements
are generally identified by the words "expects", "anticipates",
"believes", "intends", "estimates", "plans" and similar expressions.
Although Sanofi's management believes that the expectations reflected
in such forward-looking statements are reasonable, investors are
cautioned that forward-looking information and statements are subject
to various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of Sanofi, that could cause
actual results and developments to differ materially from those
expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include
among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or
the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential of
such product candidates, the absence of guarantee that the product
candidates if approved will be commercially successful, the future
approval and commercial success of therapeutic alternatives, the
Group's ability to benefit from external growth opportunities, trends
in exchange rates and prevailing interest rates, the impact of cost
containment policies and subsequent changes thereto, the average
number of shares outstanding as well as those discussed or identified
in the public filings with the SEC and the AMF made by Sanofi,
including those listed under "Risk Factors" and "Cautionary Statement
Regarding Forward-Looking Statements" in Sanofi's annual report on
Form 20-F for the year ended December 31, 2013. Other than as
required by applicable law, Sanofi does not undertake any obligation
to update or revise any forward-looking information or statements.

Cpntact:
Sanofi